

Brent L Wood

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1155829/publications.pdf>

Version: 2024-02-01

198
papers

15,529
citations

38742

50
h-index

18647

119
g-index

200
all docs

200
docs citations

200
times ranked

16716
citing authors

#	ARTICLE	IF	CITATIONS
1	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	27.0	1,443
2	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 2012, 481, 157-163.	27.8	1,430
3	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine, 2016, 8, 355ra116.	12.4	832
4	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2018, 131, 1275-1291.	1.4	796
5	Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies. Cancer Prevention Research, 2012, 5, 492-497.	1.5	784
6	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics, 2017, 49, 1211-1218.	21.4	693
7	Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia. JAMA Oncology, 2017, 3, e170580.	7.1	388
8	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
9	Cord-Blood Transplantation in Patients with Minimal Residual Disease. New England Journal of Medicine, 2016, 375, 944-953.	27.0	352
10	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. Journal of Clinical Oncology, 2016, 34, 329-336.	1.6	347
11	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood, 2013, 122, 1813-1821.	1.4	325
12	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	1.4	305
13	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. Journal of Clinical Oncology, 2016, 34, 2380-2388.	1.6	301
14	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood, 2015, 126, 964-971.	1.4	287
15	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	21.4	264
16	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood, 2017, 129, 3352-3361.	1.4	236
17	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. Journal of Molecular Diagnostics, 2014, 16, 56-67.	2.8	234
18	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	12.8	218

#	ARTICLE	IF	CITATIONS
19	Î³-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. <i>Blood</i> , 2019, 134, 1585-1597.	1.4	209
20	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. <i>Haematologica</i> , 2017, 102, 865-873.	3.5	206
21	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	9.4	201
22	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	1.6	185
23	A phase I/II trial of iodine-131-anti-CD20 (tositumomab), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	1.4	173
24	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 995-999.	1.4	170
25	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	1.6	164
26	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. <i>Blood</i> , 2018, 131, 1350-1359.	1.4	158
27	Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part V - assay performance criteria. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84, 315-323.	1.5	153
28	Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of <i>IGH</i> . <i>Clinical Cancer Research</i> , 2014, 20, 4540-4548.	7.0	138
29	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	1.6	136
30	Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. <i>Blood Reviews</i> , 2017, 31, 63-75.	5.7	128
31	9-Color and 10-Color Flow Cytometry in the Clinical Laboratory. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 680-690.	2.5	124
32	<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018, 36, 591-599.	1.6	121
33	Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 47-53.	1.5	118
34	Four-Color Flow Cytometry Shows Strong Concordance With Bone Marrow Morphology and Cytogenetics in the Evaluation for Myelodysplasia. <i>American Journal of Clinical Pathology</i> , 2005, 124, 170-181.	0.7	116
35	Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial. <i>Blood</i> , 2017, 130, 811-811.	1.4	109
36	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2020, 38, 602-612.	1.6	107

#	ARTICLE	IF	CITATIONS
37	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. <i>Blood</i> , 2018, 132, 815-824.	1.4	97
38	Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 341-350.	2.0	95
39	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. <i>Journal of Clinical Oncology</i> , 2022, 40, 932-944.	1.6	93
40	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	1.6	91
41	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 1011-1011.	1.4	91
42	A novel flow cytometric assay for detection of residual disease in patients with B-cell lymphoblastic leukemia/lymphoma post anti-CD19 therapy. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 112-120.	1.5	84
43	Multicolor Immunophenotyping: Human Immune System Hematopoiesis. <i>Methods in Cell Biology</i> , 2004, 75, 559-576.	1.1	76
44	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	1.5	76
45	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2527-2534.	1.6	64
46	Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. <i>Leukemia Research and Treatment</i> , 2014, 2014, 1-9.	2.0	63
47	Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 256-265.	1.5	59
48	Flow Cytometric Monitoring of Residual Disease in Acute Leukemia. <i>Methods in Molecular Biology</i> , 2013, 999, 123-136.	0.9	57
49	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021, 39, 1437-1447.	1.6	56
50	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10500-10500.	1.6	54
51	Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. <i>Blood Advances</i> , 2023, 7, 575-585.	5.2	52
52	T-Cell Clonality Determination Using Polymerase Chain Reaction (PCR) Amplification of the T-Cell Receptor gamma-Chain Gene and Capillary Electrophoresis of Fluorescently Labeled PCR Products. <i>American Journal of Clinical Pathology</i> , 2000, 113, 838-850.	0.7	51
53	Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 204-204.	1.4	50
54	Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. <i>Modern Pathology</i> , 2014, 27, 1438-1446.	5.5	49

#	ARTICLE	IF	CITATIONS
55	Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. Current Protocols in Cytometry, 2020, 93, e73.	3.7	49
56	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. Blood, 2015, 126, 184-184.	1.4	49
57	Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part I - rationale and aims. , 2013, 84, 282-285.		48
58	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 2126-2137.	7.2	48
59	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 549-555.	2.0	47
60	Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 691-696.	2.0	46
61	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer, 2018, 124, 1150-1159.	4.1	46
62	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. Journal of Clinical Oncology, 2022, 40, 2106-2118.	1.6	45
63	Four-Color Flow Cytometry Identifies Virtually All Cytogenetically Abnormal Bone Marrow Samples in the Workup of Non-CML Myeloproliferative Disorders. American Journal of Clinical Pathology, 2003, 120, 854-865.	0.7	44
64	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	1.4	44
65	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2022, 40, 1574-1582.	1.6	44
66	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. Journal of Clinical Oncology, 2020, 38, 3062-3070.	1.6	42
67	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. Journal of Clinical Oncology, 2020, 38, 2628-2638.	1.6	41
68	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). Leukemia, 2018, 32, 1370-1379.	7.2	40
69	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3773-3773.	1.4	39
70	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 3094-3114.	8.5	37
71	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2016, 22, 1227-1233.	2.0	36
72	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. Journal of Clinical Investigation, 2020, 130, 863-876.	8.2	36

#	ARTICLE	IF	CITATIONS
73	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 1174-1185.	1.6	36
74	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. <i>HemaSphere</i> , 2022, 6, e676.	2.7	35
75	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019, 238, 62-68.	0.4	32
76	Mixedâ€‘phenotype acute leukemia: A cohort and consensus research strategy from the Childrenâ€™s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020, 126, 593-601.	4.1	32
77	Methods of Detection of Measurable Residual Disease in AML. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 557-567.	2.3	31
78	CD44 promotes chemoresistance in T-ALL by increased drug efflux. <i>Experimental Hematology</i> , 2016, 44, 166-171.e17.	0.4	29
79	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1615-1620.	2.0	29
80	Evaluation of allogeneic transplantation in first or later minimal residual disease â€‘ negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2109-2118.	1.3	28
81	Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. <i>Haematologica</i> , 2017, 102, 1549-1557.	3.5	28
82	How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 237-248.	1.7	28
83	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Cancers</i> , 2020, 12, 2339.	3.7	28
84	Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated <i>NPM1</i>. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 67-72.	1.5	26
85	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019, 104, 986-992.	3.5	25
86	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1226-1233.	1.3	24
87	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of inductionâ€‘A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2009, 114, 9-9.	1.4	24
88	A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 211-211.	1.4	24
89	Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. <i>American Journal of Pathology</i> , 2017, 187, 304-317.	3.8	22
90	AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. <i>Biomarker Research</i> , 2020, 8, 29.	6.8	22

#	ARTICLE	IF	CITATIONS
91	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020, 34, 1577-1587.	7.2	22
92	Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. <i>Blood</i> , 2021, 137, 569-572.	1.4	21
93	Human <sc>B</sc>-cell and progenitor stages as determined by probability state modeling of multidimensional cytometry data. <i>Cytometry Part B - Clinical Cytometry</i> , 2015, 88, 214-226.	1.5	20
94	Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells.. <i>Journal of Clinical Oncology</i> , 2016, 34, 102-102.	1.6	20
95	Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021, 39, 1540-1552.	1.6	19
96	On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. <i>Blood</i> , 2013, 122, 1341-1341.	1.4	19
97	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
98	The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 43, 100650.	5.7	17
99	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e97-e98.	3.5	16
100	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	6.3	16
101	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , 2020, 34, 1701-1705.	7.2	15
102	Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3006-3006.	1.6	15
103	Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase. <i>Blood</i> , 2019, 134, 1856-1856.	1.4	14
104	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 565-565.	1.4	14
105	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. <i>Leukemia</i> , 2022, 36, 648-655.	7.2	14
106	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. <i>American Journal of Hematology</i> , 2018, 93, 546-552.	4.1	13
107	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 669-672.	2.4	13
108	Computer-Aided Detection of Rare Tumor Populations in Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 2015, 144, 517-524.	0.7	12

#	ARTICLE	IF	CITATIONS
109	Flow cytometric features of incidental indolent T lymphoblastic proliferations. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 282-287.	1.5	12
110	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. <i>Blood</i> , 2013, 122, 2550-2550.	1.4	12
111	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 1863-1870.	4.1	12
112	Clinical Experience With Modified, Single-Tube T-Cell Receptor V β 2 Flow Cytometry Analysis for T-Cell Clonality. <i>American Journal of Clinical Pathology</i> , 2016, 145, 467-485.	0.7	11
113	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019, 104, e517-e520.	3.5	11
114	Immunophenotypic Features of Myeloid Neoplasms Associated with Chromosome 7 Abnormalities. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 300-309.	1.5	11
115	The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2479-2483.	7.2	11
116	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky069.	2.9	10
117	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29256.	1.5	10
118	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231. <i>Blood</i> , 2020, 136, 11-12.	1.4	10
119	Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.. <i>Blood</i> , 2007, 110, 159-159.	1.4	10
120	KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 256-256.	1.4	10
121	Measurable Residual Disease Detection in Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method. <i>Current Protocols</i> , 2022, 2, e383.	2.9	10
122	Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 387-392.	1.5	9
123	Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid. <i>British Journal of Haematology</i> , 2016, 172, 134-136.	2.5	9
124	Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas. <i>Methods in Molecular Biology</i> , 2019, 1956, 35-60.	0.9	9
125	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.	1.5	9
126	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children's Oncology Group AALL0622.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10006-10006.	1.6	9

#	ARTICLE	IF	CITATIONS
127	Flow cytometry in the diagnosis and monitoring of acute leukemia in children. Journal of Hematopathology, 2015, 8, 191-199.	0.4	8
128	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatric Blood and Cancer, 2019, 66, e27681.	1.5	8
129	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia, 2019, 33, 554-558.	7.2	8
130	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after "Day 14"™ without further therapy in acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2717-2719.	1.3	7
131	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. Blood, 2018, 132, 35-35.	1.4	7
132	Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy. Blood, 2020, 136, 11-12.	1.4	7
133	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. Blood, 2009, 114, 1580-1580.	1.4	7
134	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report.. Journal of Clinical Oncology, 2020, 38, 10510-10510.	1.6	7
135	Plasma polychlorinated biphenyl concentrations and immune function in postmenopausal women. Environmental Research, 2014, 131, 174-180.	7.5	6
136	Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. Biopreservation and Biobanking, 2018, 16, 42-52.	1.0	6
137	Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932. Blood, 2019, 134, 824-824.	1.4	6
138	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. Blood, 2020, 136, 45-46.	1.4	6
139	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia, 2022, 36, 1499-1507.	7.2	6
140	Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2022, , .	2.5	6
141	Early T-cell Precursor Acute Lymphoblastic Leukemia in an Infant With an <i>NRAS</i> Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. Pediatric Blood and Cancer, 2016, 63, 1667-1670.	1.5	5
142	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). Blood, 2015, 126, 807-807.	1.4	5
143	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
144	CD44H and CD44V6 Expression in Different Subtypes of Hodgkin Lymphoma. Modern Pathology, 2000, 13, 1121-1127.	5.5	4

#	ARTICLE	IF	CITATIONS
145	A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 340-340.	1.4	4
146	CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Advances, 2023, 7, 251-255.	5.2	4
147	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children's Oncology Group AALL1131.. Journal of Clinical Oncology, 2021, 39, 10004-10004.	1.6	3
148	The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia. Blood, 2012, 120, 1418-1418.	1.4	3
149	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. Journal of Clinical Oncology, 2020, 38, 10509-10509.	1.6	3
150	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers, 2021, 13, 5607.	3.7	3
151	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. Blood, 2021, 138, 3398-3398.	1.4	3
152	Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 15-15.	1.4	3
153	No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. Experimental Hematology, 2014, 42, 497-504.	0.4	2
154	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatric Blood and Cancer, 2021, 68, e28574.	1.5	2
155	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). Blood, 2018, 132, 1000-1000.	1.4	2
156	Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model. Blood, 2013, 122, 882-882.	1.4	2
157	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. Blood, 2016, 128, 1086-1086.	1.4	2
158	Next-Generation Sequencing for Measurable Residual Disease Assessment in Acute Leukemia. Advances in Molecular Pathology, 2021, 4, 49-63.	0.4	2
159	Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/Lymphoma. Blood, 2019, 134, 1475-1475.	1.4	2
160	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. Blood, 2020, 136, 39-40.	1.4	2
161	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. Bone Marrow Transplantation, 2019, 54, 1511-1514.	2.4	1
162	Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow. Blood, 2019, 134, 2729-2729.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2569-2569.	1.4	1
164	The value of secondary pathology review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7-7.	1.6	1
165	VpreB Surrogate Light Chain Expression in B-Lineage ALL: A Report from the Children's Oncology Group. <i>Blood Advances</i> , 2021, , .	5.2	1
166	Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.. <i>Blood</i> , 2009, 114, 2658-2658.	1.4	1
167	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Blood</i> , 2015, 126, 2571-2571.	1.4	1
168	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-L) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3487-3487.	1.4	1
169	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 614-614.	1.4	1
170	Standardization in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL): Semiquantitative, Universally Applicable Flow Cytometric Criteria for Immunophenotypic Lineage Assignment and Isolated MPO. <i>Blood</i> , 2021, 138, 4475-4475.	1.4	1
171	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020, 136, 44-45.	1.4	1
172	Pre-B cell receptor expression in B-lineage acute lymphoblastic leukemia: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19006-e19006.	1.6	0
173	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10002-10002.	1.6	0
174	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10003-10003.	1.6	0
175	In Vivo Expansion of Transduced Human Erythroid Cells Using an Mpl-Based Cell Growth Switch.. <i>Blood</i> , 2004, 104, 2100-2100.	1.4	0
176	Expansion of Genetically Modified Primary Human Hematopoietic Cells Using a Cell Growth Switch.. <i>Blood</i> , 2005, 106, 3044-3044.	1.4	0
177	Identification and Purification of Hodgkin Cells from Lymph Nodes Involved by Classical Hodgkin Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.. <i>Blood</i> , 2006, 108, 2262-2262.	1.4	0
178	A Characterization of Microparticles in Stored Packed Red Blood Cell Units.. <i>Blood</i> , 2006, 108, 4147-4147.	1.4	0
179	Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. <i>Blood</i> , 2012, 120, 655-655.	1.4	0
180	Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. <i>Blood</i> , 2012, 120, 1440-1440.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Rapid Rate of Peripheral Blood Blast Clearance Accurately Predicts Complete Remission in Acute Myeloid Leukemia. Blood, 2012, 120, 3551-3551.	1.4	0
182	Detection Of Recurrent/Persistent Disease By T-Cell Receptor Repertoire Profiling In Patients With Mature T-Cell Neoplasm. Blood, 2013, 122, 2614-2614.	1.4	0
183	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. Blood, 2013, 122, 1317-1317.	1.4	0
184	Discrepancy in bone marrow blast counts between morphology and flow cytometry and its potential clinical implications.. Journal of Clinical Oncology, 2015, 33, e18031-e18031.	1.6	0
185	Pathophysiology of Macrocytic Anemia in Diamond Blackfan Anemia and Del(5q) Myelodysplastic Syndrome. Blood, 2015, 126, 670-670.	1.4	0
186	Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. Blood, 2016, 128, 2890-2890.	1.4	0
187	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. Blood, 2018, 132, 5255-5255.	1.4	0
188	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. Blood, 2018, 132, 3978-3978.	1.4	0
189	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. Blood, 2018, 132, 889-889.	1.4	0
190	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. Blood, 2018, 132, 659-659.	1.4	0
191	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2019, 37, 10033-10033.	1.6	0
192	Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. Blood, 2019, 134, 2691-2691.	1.4	0
193	Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease. Blood, 2019, 134, 321-321.	1.4	0
194	Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232. Blood, 2019, 134, 286-286.	1.4	0
195	Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count. Blood, 2019, 134, 2692-2692.	1.4	0
196	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. Blood, 2021, 138, 2382-2382.	1.4	0
197	Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States. Blood, 2021, 138, 4478-4478.	1.4	0
198	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. Blood, 2020, 136, 38-39.	1.4	0